Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers.

British journal of cancer - 8 Aug 2005

van Sprundel T C, Schmidt M K, Rookus M A, Brohet R, van Asperen C J, Rutgers E J Th, Van't Veer L J, Tollenaar R A E M

Abstract excerpt

The clinical outcome of contralateral prophylactic mastectomy (CPM) in women with a BRCA1 or BRCA2 mutation and a personal history of invasive breast cancer is unknown. We identified a cohort of 148 female BRCA1 or BRCA2 mutation carriers (115 and 33, respectively) who previously were treated for unilateral invasive breast cancer stages I-IIIa. In all, 79 women underwent a CPM, while the other women remained...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Functional Laterality

Share to Mastectomy

Share to Neoplasms, Second Primary

Share to Ovariectomy

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 16052221
DOI: 10.1038/sj.bjc.6602703
PMCID: PMC2361560

Genes

CPM
BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers.PMID 16052221Read ↗

Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis.Semantic proximity Read ↗

Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer.Semantic proximity Read ↗

Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer.Semantic proximity Read ↗

Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysisSemantic proximity Read ↗

Contralateral breast cancer and tumor recurrence in BRCA1/2 carriers and non-carriers at a high risk of hereditary breast cancer after bilateral mastectomy.Semantic proximity Read ↗

Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy.Semantic proximity Read ↗

Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability.Semantic proximity Read ↗

Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.Semantic proximity Read ↗

Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.Semantic proximity Read ↗

Prophylactic mastectomy for the prevention of breast cancer.Semantic proximity Read ↗

Survival Outcomes in Women with Unilateral, Triple-Negative, Breast Cancer Correlated with Contralateral Prophylactic Mastectomy.Semantic proximity Read ↗

Bilateral breast cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.